A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.

Abstract excerpt

DYRK1A is important in neuronal development and function, and its excessive activity is considered a significant pathogenic factor in Down syndrome and Alzheimer's disease. Thus, inhibition of DYRK1A has been suggested to be a new strategy to modify the disease. Very few compounds, however, have been reported to act as inhibitors, and their potential clinical uses require further evaluation. Here, we newly...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Administration, Oral
• Share to Amyloid beta-Protein Precursor